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Abstracts
Social health insurance is mandatory in Switzerland and cov-
ers the costs of basic medical care. In general, with regard to 
medicines, the costs are only reimbursed if the drug is (1) ap-
proved by Swissmedic and (2) listed on the so-called Spezia-
litätenliste (SL) by the Federal Office of Public Health (FOPH). 
However, the SL does not include all drugs. For non-SL drugs, 
cost coverage is only granted under exceptional circum-
stances. Absence of cost coverage by social health insurance 
is especially problematic for patients who need access to 
cancer drugs, since they are often costly. Even if such cancer 
drugs are approved by Swissmedic, patients may still lack ac-
cess to them. Therefore, access to medicines includes two 
aspects: (1) the availability of a drug on the market (i.e., ap-
proval of a drug) and (2) inclusion on the SL (i.e., cost cover-
age by social health insurance). In this study, we aim to com-
pare the current approval regulations for oncologic preci-
sion medicines in the USA, Europe, and Switzerland; to 
investigate cost coverage for these drugs in Switzerland; and 
to develop health policy implications about how access to 
these drugs could be improved in Switzerland.
© 2019 S. Karger AG, Basel
Introduction
Over a hundred new cancer drugs have been approved 
by Swissmedic, the European Medicines Agency (EMA), 
and the US Food and Drug Administration (FDA), and 
over 38,000 cancer drug trials have been initiated since 
2000. A shift can be observed from the development of 
classic chemotherapeutic drugs to immunotherapies and 
biomarker-defined cancer drugs, also known as preci-
sion medicines or precision drugs [1, 2].
At the same time, health costs are rising continuously. 
In 2016, the total health costs in Switzerland amounted 
to more than CHF 80 billion, which is an increase of 3.7% 
compared to 2015 [3]. Expenditures on pharmaceutical 












































































Access to Cancer Precision Medicines in 
Switzerland
239Public Health Genomics 2018;21:238–243
DOI: 10.1159/000501562
to USD 666 per capita, which is approximately 30% above 
the OECD average [4]. This expenditure increased to 
USD 982 in 2016 [5]. A major reason for this great in-
crease lies in certain high-cost drugs, such as oncology 
drugs. In 2016, the costs of cancer drugs amounted to 
CHF 500 million [5].
Social health insurance is mandatory in Switzerland 
and covers the costs of basic medical care. In general, 
it only covers the costs of medicines that are (1) ap-
proved by Swissmedic and (2) listed on the so-called 
Spezialitätenliste (SL) by the Federal Office of Public 
Health (FOPH). The FOPH decides whether a specific 
drug should be included on the SL, and if so, deter-
mines the maximum price in negotiation with the 
manufacturer. However, the SL does not include all 
drugs. For non-SL drugs, cost coverage is only granted 
under exceptional circumstances. Absence of cost cov-
erage is often problematic for patients since cancer 
drugs can be very costly. Therefore, even if such cancer 
drugs are approved by Swissmedic, patients may still 
lack access to them. In sum, access to medicines in-
cludes two aspects: (1) the availability of a drug on the 
market (i.e., approval of a drug) and (2) cost coverage 
by social health insurance.
In this study, we aim (a) to compare the current ap-
proval regulations for oncologic precision medicines in 
the USA, Europe, and Switzerland; (b) to investigate cost 
coverage for these drugs in Switzerland; and (c) to assess 
health policy implications about how access to these 
drugs could be improved in Switzerland.
Opportunities and Challenges of Precision Medicine
The general concept of personalized medicine is de-
cades old [6]. However, the mapping of the human ge-
nome, completed in 2003, increased the volume of avail-
able genetic data and raised the expectation that gene-
based drugs would enable new and promising ap- 
proaches to successful treatment, especially in oncology 
[7, 8]. The project led to an increased understanding of 
the molecular pathways that underlie cancer [9]. The 
term precision medicine can be understood as targeted 
diagnosis and therapy, i.e., an approach that takes indi-
vidual variability – particularly genetic variation – into 
account when developing medical treatments [10]. Some 
precision medicines have become standards of care, 
e.g., trastuzumab for HER2-positive breast cancer or 
vemurafenib for melanomas that express mutated BRAF 
(Table 1) [10–12].
Precision drugs are supposed to offer a greater clinical 
benefit or reduced side effects to the targeted patient 
populations [13]. However, targeting a specific muta- 
tion – and, therefore, a smaller patient population – may 
also result in smaller clinical trial sizes and an increased 
use of surrogate endpoints in clinical trials [2]. A study 
showed that precision medicines approved by the FDA 
in 2013–2017 were based on fewer pivotal trials that were 
less likely to be randomized, blinded, or controlled with 
either an active or a placebo comparator [2]. For exam-
ple, the pivotal trials for the approval of crizotinib (Xalko-
ri) in 2011 by the FDA were based on two single-arm 
studies with surrogate efficacy endpoints (objective re-
sponse rate) and fewer than 140 patients in each trial 
[14].
Precision medicines are regularly associated with high 
costs. For example, ibritumomab tiuxetan (Zevalin), a 
monoclonal antibody radioimmunotherapy, costs CHF 
23,520 (factory price) per infusion in Switzerland, and 
the costs of the chimeric antigen receptor T-cell therapy 
tisagenlecleucel (Kymriah) are USD 470,000 in the USA 
and EUR 320,000 in Germany. This anticancer drug is 
already approved in Switzerland by Swissmedic, but the 
FOPH did not yet set the price. Most likely, it will also be 
high in Switzerland. Novartis expects a price of CHF 
370,000 [15]. Nonetheless, advocates of precision medi-
cines emphasize the lower treatment costs overall [13]. 
However, various cost-effectiveness studies have dem-
onstrated the opposite. For example, in an individual-
based intervention study by the public health services of 
Norway, a single-agent biomarker-based approach was 
2.5 times more expensive than best supportive care [13, 
16]. Furthermore, for most patients with metastatic can-
cer, the duration of benefit is limited, and is followed by 
drug resistance and cancer progression [9].





Xalkori (crizotinib) ALK+ Non-small cell lung 
cancer after progression 
on first-line therapy
Zykadia (ceritinib) ALK+ Non-small cell lung 
cancer for patients 
resistant or intolerant to 
treatment with crizotinib
Herceptin (trastuzumab) HER2+ Breast cancer
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Approval for Precision Medicines in the USA, EU,  
and Switzerland
In general, before a drug can be sold widely in a coun-
try, it must have been approved by a national agency. In 
the USA, approval is being granted by the FDA, in the EU 
by the EMA, and in Switzerland by Swissmedic. The 
agencies must determine, based on the data they receive, 
whether a drug is of high quality, is safe, and has the effect 
it is meant to have based on adequate and well-controlled 
investigations (such as randomized controlled trials as-
sessing validated clinical outcomes) [17]. The agencies 
make these determinations by reviewing the results of 
these clinical studies by – or on behalf of – the manufac-
turer [17]. The approval process can be time-consuming 
(e.g., in the USA, the FDA must review the data within a 
10-month window) and may delay access to medicines 
for patients. This can be especially problematic for pa-
tients with serious or life-threatening conditions who 
have no other treatment options [17]. In response, regula-
tors and legislators in the USA, the EU, and Switzerland 
created different programs or designations to expedite 
approval for promising new drugs intended for unmet 
medical needs (Table 2). These programs are not congru-
Table 2. Accelerated programs in the USA, the EU, and Switzerland
FDA EMA Swissmedic
Program name Eligibility Program name Eligibility Program name Eligibility
Orphan Drug 
Designation
Drug treats disease occurring in <200,000 
people per year in the USA, or in more than 
200,000 people but for which there are no 
reasonable expectations that the drug 
development costs will be recovered
Orphan Drug 
Designation
Drug must be intended for treatment, 
prevention, or diagnosis of a disease that is 
life-threatening or chronically debilitating;
the prevalence of the condition in the EU must 
not be more than 5 in 10,000 or it must be 
unlikely that marketing of the drug would 
generate sufficient returns to justify the 
investment needed for its development; and 
no satisfactory method of diagnosis, 
prevention, or treatment of the condition 
concerned can be authorized, or, if such 
methods exist, the drug must be of significant 






1. Drug treats life-threatening or severely 
debilitating disease, and disease occurs in 
max. 5/10,000 people in Switzerland; or
2. Drug has been designated in another 
country by a comparable approval agency as 
an important drug for orphan diseases
Fast Track 1. Drug treats life-threatening or severely 
debilitating diseases, and nonclinical or 
clinical data demonstrate the potential to 
address unmet medical needs; or
2. Drug is designated as a qualified infectious 
disease product
PRIME Drug of major interest for public health, in 
particular from the viewpoint of therapeutic 






1. Drugs with known active pharmaceutical 
ingredients; or
2. Complementary drugs; or
3. Drugs prepared for stocks by a public 
pharmacy, a drugstore, or another 
establishment holding a manufacturing 
license; or
4. Drugs prepared by a hospital pharmacy or 
in the hospital’s own radiopharmaceutical 
unit for the needs of the hospital; or
5. Drugs prepared by the army and used in 
the context of the coordinated army medical 
corps; or
6. Important drugs for rare diseases
Priority Review 1. Drug treats serious condition and, if 
approved, would provide a significant 
improvement in safety or effectiveness; or
2. Any supplement that proposes a labeling 
change pursuant to a report on a pediatric 
study; or
3. An application for a drug that has been 
designated as a qualified infectious disease 
product; or
4. Any application or supplement for a drug 
submitted with a priority review voucher 
Accelerated 
Assessment
Drugs of major interest for public health, in 
particular from the viewpoint of therapeutic 
innovation (unmet medical needs)
Accelerated 
Approval
Drug intended to treat a serious condition;
generally provides a meaningful advantage 
over available therapies; and
demonstrates an effect on a surrogate 





Drug for seriously debilitating or life-threaten-
ing disease, including orphan drugs, fulfilling 
the following criteria:
positive risk-benefit balance;
applicant likely to be able to provide compre-
hensive data after authorization;
drug fulfils unmet medical needs;
benefits of immediate availability outweigh 





Drug treats life-threatening or disabling 
disease;
approval in accordance with human health;
high clinical benefit is expected; and 




1. Drug intended to treat a serious condition, 
and nonclinical or clinical data demonstrate 
its potential to address unmet medical needs; 
or
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ent between jurisdictions; however, they have similarities, 
and eligibility criteria regularly overlap. Depending on 
the program, among other things, the assessment time for 
marketing authorization is shorter, a drug can be (condi-
tionally) authorized on the basis of less complete clinical 
data, or more guidance on drug development is being 
granted [2, 17].
All three jurisdictions implemented the so-called or-
phan drug designation (Table 2). In 2016 alone, orphan 
designation was sought for 568 products in the USA. Six 
of the top 10 by revenue were designated as orphan drugs 
for oncology diagnoses, with annual sales ranging from 
USD 1.1 billion to 4.4 billion [18, 19]. Furthermore, stud-
ies analyzing drugs approved between 2002 and 2015 
have shown that approximately 40–45% of all orphan 
drug designations are requested for rare cancers [20, 21]. 
The number of biomarker-derived cancer drugs that are 
being designated orphan status is yearly increasing as well 
[20]. These high revenues achieved with drugs that, in 
fact, are not used for treating true orphan diseases are in 
conflict with regulators’ aims in the different jurisdictions 
[22]. Unfortunately, only little information on these ap-
proval data is publicly available in Switzerland. There-
fore, it may only be assumed that the patterns observed in 
the USA apply to Switzerland as well.
Cost Coverage for Precision Medicines and 
Fundamental Rights in Switzerland
Fundamental rights are rights recognized and sup-
ported by the government that are retained by each indi-
vidual, such as the right to life, prohibition of the death 
penalty, prohibition of discrimination, or the right to pri-
vacy [23].
Based on the non-discrimination principle in Art. 8 
para. 2 Cst., all patients must have, among other things, 
equal access to medicines [24], i.e., patients suffering 
from orphan diseases must have equal access to drugs 
compared to patients who are diagnosed with non-or-
phan diseases. However, in general, manufacturers have 
a greater incentive to develop drugs for diseases that affect 
larger populations to maximize their profits. Therefore, 
the government developed expedited pathways, as out-
lined in Table 2, to incentivize, among other things, the 
development of orphan drugs and fulfil the requirements 
of the non-discrimination principle [25].
Additionally, a fundamental right relevant to access to 
medicines is Art. 12 Cst., which states that persons in 
need and unable to provide for themselves have the right 
to assistance and care, and to the financial means required 
for a decent standard of living. Based on this provision, 
the question arises whether there is a fundamental right 
to access to health and medicine in Switzerland. The ma-
jority of Swiss legal scholars denies this and does not rec-
ognize access to medicine as a fundamental right [24, 25]. 
Moreover, the scope of application of Art. 12 Cst. is lim-
ited to emergency situations, i.e., minimal survival sup-
port [26–28]. However, even though the Swiss constitu-
tion does not comprise a fundamental right to medicine, 
Art. 41 Cst. contains the social objectives that must be 
addressed by the Swiss Confederation and the cantons. 
Among other things, the Swiss constitution gives the gov-
ernment the mandate to ensure that there is sufficient 
high-quality basic medical care available to all [29]. One 
major tool for fulfilling this objective is everyone’s re-
sponsibility to be insured with a social health insurance 
agency. This agency covers the costs of basic medical care 
if a specific medical procedure, including the prescription 
of drugs, is expedient, has a clinical benefit, and is eco-
nomical (i.e., has a good cost-benefit ratio) [24].
In general, the cost of a drug is covered by the social 
health insurance agency if it is (1) approved by Swissmed-
ic and (2) listed on the SL. The FOPH only adds a drug to 
the SL if it fulfills the basic requirements outlined above 
(expediency, clinical benefit, and economy). However, 
not all cancer drugs are on the SL. Drugs that are not con-
sidered having a clinical benefit or a good cost-benefit 
ratio, or are not considered basic medical care, will not be 
included on the list.
Nonetheless, under specific circumstances, the social 
health insurance agency is legally required to cover the 
costs of an approved non-SL drug if (a) use of the drug is 
an indispensable prerequisite for the performance of an-
other medical service covered by the social health insur-
ance agency or (b) use of the drug is expected to provide 
a significant therapeutic benefit against a disease that is 
fatal to the insured patient or may result in severe and 
chronic adverse health effects, and no other effective and 
approved treatment is available due to a lack of therapeu-
tic alternatives [30, 31]. With regard to cancer drugs, the 
second condition (b) is relevant. In an application for cost 
coverage (“Kostengutsprache”) to the patient’s social 
health insurance agency, it is the responsibility of the pa-
tient to prove that, in this specific case, the abovemen-
tioned prerequisites are met. In practice, such applica-
tions for cost coverage in most cases are written by the 
treating physician. The social health insurance agency 
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In oncology, the most challenging prerequisite to 
prove is that of a significant therapeutic benefit. The term 
is ambiguous and there is no clear understanding of what 
it actually means. A further challenge is that social health 
insurance agencies have considerable discretionary pow-
er when deciding on whether or not the prerequisites for 
cost coverage are met. Additionally, cost coverage in these 
individual cases strongly depends on the quality of the 
application for cost coverage, and therefore on the quali-
fications and efforts of the physician in charge. Due to 
these circumstances, it is possible that some patients get 
cost coverage from one social health insurance agency, 
while other patients are not granted cost coverage by 
(other) social health insurance agencies [32]. This con-
tains an element of arbitrariness and is unfortunate con-
sidering patients’ fundamental rights – and also consider-
ing that the number of non-SL precision drugs in oncol-
ogy may increase in the near future if manufacturers are 
going to have (increasingly) high price expectations and 
negotiations with the FOPH will not succeed. It is essen-
tial that, as a rule, the costs of (precision cancer) drugs 
with a clinical benefit are covered by social health insur-
ance agencies, and that cost coverage via Art. 71a et seq. 
KVV will only apply in exceptional cases.
Conclusion and Implications
Precision medicines in oncology enable promising ap-
proaches to successful treatment. Only drugs that offer 
high clinical benefit and address unmet medical needs 
should be approved through expedited regulatory ap-
proval, which includes, among other things, shorter re-
view times and fewer clinical trials. More and more, pre-
cision medicines are approved through expedited path-
ways in the USA, and it may be assumed that this is also 
true for Switzerland. Therefore, the exception increasing-
ly becomes the rule. Applying expedited regulatory ap-
proval in circumstances where the precondition of a great 
clinical benefit is not met wastes resources that might oth-
erwise have been used for drugs with high clinical benefit.
To facilitate research in this field, and thereby improve 
the validity of its implications, detailed information about 
the drug approval and health technology assessment pro-
cess in Switzerland should be publicly available. Further-
more, the increasing health care costs raise questions re-
garding cost coverage. It is essential that the pricing of 
drugs is based on their clinical value and that drugs with 
a clinical benefit are prioritized for listing on the SL. 
Moreover, the application and decision-making process 
regarding cost coverage for drugs not listed on the SL 
should be standardized to minimize access inequality and 
comply with the Swiss fundamental rights.
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